Utilization of Boron Compounds for the Modification of Suberoyl Anilide Hydroxamic Acid as Inhibitor of Histone Deacetylase Class II Homo sapiens

Table 7

Ligand bioavailability.

Ligand	Egan’s rule	Veber’s rule	Bioavability
			% (Oral) > 30%	% (Oral) > 70%
Nova2 (9058064-6)	Good	Low	0.03	0.01
Nova2 (95752-88-8)	Good	Good	0.85	0.48
Nova2 (88765-82-6)	Good	Good	0.85	0.27
Nova2 (Unique10)	Good	Good	0.76	0.27
Nova2 (16876-27-0)	Good	Good	0.85	0.48
Nova2 (513246-99-6)	Good	Good	0.76	0.27
Nova2 (Unique80)	Good	Good	0.76	0.23
Nova2 (279262-23-6)	Good	Good	0.59	0.27